Todays Report: The Celldex Therapeutics Inc. (CLDX) Earns Buy Rating from Cantor Fitzgerald

The Celldex Therapeutics Inc. (CLDX) Earns Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their buy rating on shares of Celldex Therapeutics Inc. (NASDAQ:CLDX) in a research note issued to investors on Monday. Cantor Fitzgerald currently has a $9.00 price objective on the biopharmaceutical company’s stock.

Other equities research analysts have also issued research reports about the company. Jefferies Group reaffirmed a hold rating and set a $5.00 price target (up previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, August 11th. Wedbush reaffirmed a neutral rating and set a $3.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, August 9th. Finally, Brean Capital assumed coverage on Celldex Therapeutics in a research note on Tuesday, October 4th. They set a buy rating and a $16.00 price target for the company. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $7.75.

Shares of Celldex Therapeutics (NASDAQ:CLDX) opened at 3.61 on Monday. The company’s 50-day moving average price is $3.76 and its 200 day moving average price is $4.17. The firm’s market cap is $362.97 million. Celldex Therapeutics has a 1-year low of $2.96 and a 1-year high of $18.62.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. Celldex Therapeutics had a negative return on equity of 47.59% and a negative net margin of 2,383.60%. The firm earned $1.39 million during the quarter, compared to analyst estimates of $0.96 million. During the same quarter in the previous year, the company posted ($0.33) earnings per share. The company’s revenue was down 36.4% compared to the same quarter last year. On average, analysts predict that Celldex Therapeutics will post ($1.34) EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Veritable L.P. acquired a new position in shares of Celldex Therapeutics during the second quarter worth about $132,000. Bank of Montreal Can acquired a new position in shares of Celldex Therapeutics during the second quarter worth about $188,000. Canada Pension Plan Investment Board increased its position in shares of Celldex Therapeutics by 304.5% in the first quarter. Canada Pension Plan Investment Board now owns 44,900 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 33,800 shares in the last quarter. KCG Holdings Inc. increased its position in shares of Celldex Therapeutics by 103.5% in the second quarter. KCG Holdings Inc. now owns 54,297 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 27,613 shares in the last quarter. Finally, National Planning Corp increased its position in shares of Celldex Therapeutics by 3.1% in the second quarter. National Planning Corp now owns 55,246 shares of the biopharmaceutical company’s stock worth $251,000 after buying an additional 1,650 shares in the last quarter. Institutional investors own 78.41% of the company’s stock.

Celldex Therapeutics Company Profile

Related posts

Leave a Comment